<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhao YT</submitter><funding>NCATS NIH HHS</funding><funding>NIDCR NIH HHS</funding><funding>Institute of Translational Health Sciences</funding><funding>NHLBI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>National Institute of Dental and Craniofacial Research</funding><funding>National Institutes of Health</funding><funding>NIGMS NIH HHS</funding><pagination>e53471</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8647152</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(12)</volume><pubmed_abstract>Angiopoietins 1 and 2 (Ang1 and Ang2) regulate angiogenesis through their similar F-domains by activating Tie2 receptors on endothelial cells. Despite the similarity in the underlying receptor-binding interaction, the two angiopoietins have opposite effects: Ang1 induces phosphorylation of AKT, strengthens cell-cell junctions, and enhances endothelial cell survival while Ang2 can antagonize these effects, depending on cellular context. To investigate the molecular basis for the opposing effects, we examined the phenotypes of a series of computationally designed protein scaffolds presenting the Ang1 F-domain in a wide range of valencies and geometries. We find two broad phenotypic classes distinguished by the number of presented F-domains: Scaffolds presenting 3 or 4 F-domains have Ang2-lik</pubmed_abstract><journal>EMBO reports</journal><pubmed_title>F-domain valency determines outcome of signaling through the angiopoietin pathway.</pubmed_title><pmcid>PMC8647152</pmcid><funding_grant_id>TR002318</funding_grant_id><funding_grant_id>R01GM097372</funding_grant_id><funding_grant_id>P01 GM081619</funding_grant_id><funding_grant_id>U01HL099997</funding_grant_id><funding_grant_id>1P01GM081619</funding_grant_id><funding_grant_id>5R21NS099654</funding_grant_id><funding_grant_id>R21 NS099654</funding_grant_id><funding_grant_id>R01 GM097372</funding_grant_id><funding_grant_id>1R01NS118247</funding_grant_id><funding_grant_id>R01 GM083867</funding_grant_id><funding_grant_id>R01GM083867</funding_grant_id><funding_grant_id>DE021984</funding_grant_id><funding_grant_id>UO1HL099993</funding_grant_id><funding_grant_id>T90 DE021984</funding_grant_id><funding_grant_id>U01 HL099997</funding_grant_id><funding_grant_id>TL1 TR002318</funding_grant_id><funding_grant_id>U01 HL099993</funding_grant_id><funding_grant_id>R01 NS118247</funding_grant_id><pubmed_authors>Xavier Raj I</pubmed_authors><pubmed_authors>Ruohola-Baker H</pubmed_authors><pubmed_authors>Somasundaram L</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Baker D</pubmed_authors><pubmed_authors>Fallas JA</pubmed_authors><pubmed_authors>Zhao YT</pubmed_authors><pubmed_authors>Saini S</pubmed_authors><pubmed_authors>Zhou Z</pubmed_authors><pubmed_authors>Sellers DL</pubmed_authors><pubmed_authors>Mathieu J</pubmed_authors><pubmed_authors>Wrenn S</pubmed_authors><pubmed_authors>Carter L</pubmed_authors><pubmed_authors>Ueda G</pubmed_authors></additional><is_claimable>false</is_claimable><name>F-domain valency determines outcome of signaling through the angiopoietin pathway.</name><description>Angiopoietins 1 and 2 (Ang1 and Ang2) regulate angiogenesis through their similar F-domains by activating Tie2 receptors on endothelial cells. Despite the similarity in the underlying receptor-binding interaction, the two angiopoietins have opposite effects: Ang1 induces phosphorylation of AKT, strengthens cell-cell junctions, and enhances endothelial cell survival while Ang2 can antagonize these effects, depending on cellular context. To investigate the molecular basis for the opposing effects, we examined the phenotypes of a series of computationally designed protein scaffolds presenting the Ang1 F-domain in a wide range of valencies and geometries. We find two broad phenotypic classes distinguished by the number of presented F-domains: Scaffolds presenting 3 or 4 F-domains have Ang2-lik</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-05-29T18:52:42.118Z</modification><creation>2024-12-04T08:20:18.751Z</creation></dates><accession>S-EPMC8647152</accession><cross_references><pubmed>34698433</pubmed><doi>10.15252/embr.202153471</doi></cross_references></HashMap>